PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2

Pharmacogenet Genomics. 2014 Aug;24(8):409-25. doi: 10.1097/FPC.0000000000000062.

Authors

Ellen M McDonagh¹, Sotiria Boukouvala, Eleni Aklillu, David W Hein, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Palo Alto, California cDepartment of Pharmacology and Toxicology and James Graham Brown Cancer Center, University of Louisville, Kentucky, USA dDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece eDepartment of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Alleles
Arylamine N-Acetyltransferase / genetics*
Caffeine / pharmacokinetics
Gene Expression Profiling
Genomics
Genotype
Humans
Hydralazine / pharmacokinetics
Isoenzymes / genetics
Isoniazid / pharmacokinetics
Pharmacogenetics
Phenotype
Polymorphism, Genetic
Sulfamethoxazole / pharmacokinetics
Sulfasalazine / pharmacokinetics
Xenobiotics / chemistry

Substances

Isoenzymes
Xenobiotics
Hydralazine
Caffeine
Sulfasalazine
Arylamine N-Acetyltransferase
N-acetyltransferase 1
NAT2 protein, human
Sulfamethoxazole
Isoniazid

Grants and funding